United States
Print page content Print
Increase text size Decrease text size
Text Size

FLUVAC INNOVATOR®

Protection is more than a theory…

FLUVAC INNOVATOR vaccines deliver demonstrated protection against circulating contemporary equine influenza viruses (EIV). FLUVAC INNOVATOR vaccines aid in the prevention of equine influenza due to type A2 viruses; equine rhinopneumonitis due to equine herpes virus (EHV) types 1 and 4; equine encephalomyelitis due to Eastern, Western and Venezuelan viruses; and tetanus.

FLUVAC INNOVATOR is veterinarian’s first choice for flu-rhino protection.1

Expand All
  • Product Highlights

    • FLUVAC INNOVATOR is the only vaccine with EIV strain KY ’97 that has demonstrated protection against heterologous challenge with EIV strain OH ’032
    • FLUVAC INNOVATOR is the only EIV vaccine shown to help protect against clinical signs for seven months against a heterologous, dual-strain challenge3
    • In addition to EIV, FLUVAC INNOVATOR vaccines also contain both EHV-1 and EHV-4 to help protect against rhinopneumonitis
    • Only INNOVATOR vaccines are adjuvanted with MetaStim for improved immune response4
  • FLUVAC INNOVATOR

    Inject 1 mL dose intramuscularly using aseptic technique. Administer a second 1 mL dose 3 to 4 weeks after the first dose in unvaccinated or naïve horses. A 1 mL annual revaccination in previously vaccinated horses is recommended. Always read and follow label indications 

    Early revaccination may be advisable when horses are faced with an outbreak or with other conditions which might make exposure likely.

    CAUTIONS

    Store in the dark at 2º to 7ºC (35º to 45ºF). AVOID FREEZING. SHAKE WELL. Use entire contents when first opened. In some instances, transient local reactions may occur at the injection site. Do not vaccinate within 21 days before slaughter. In case of anaphylactoid reaction, administer epinephrine. Thimerosal, neomycin and polymyxin B are added as preservatives. For veterinary use only.

    1. Doane Market Research Inc. and CEESA International Sales Survey (CISS), September 2009
    2. Data on file, Study Report No. B671-08-004.R, Zoetis Inc.
    3. “Data on file, Study Report No. B671-02-001.P, Zoetis Inc.”
    4. Davis EG, et al. Investigation of Antigen Specific Lymphocyte Responses in Healthy Horses Vaccinated with an Inactivated West Nile Virus Vaccine. Vet Immunol Immunopathol 2008;126:293–301